Tagged with Cancer,

Switzerland Philippe Held, founder of the innovative Swiss medtech Dermosafe, discusses the origins behind the company’s game-changing digitalized solutions for detecting skin cancer at an early stage, how the rollout of the technology is progressing, and the importance of patient and physician education. You founded DermoSafe around five years ago with…

Brazil Dr. Wilson Pedreira, executive director of the Oncology and Hematology Center of the Albert Einstein Philanthropic Society in Brazil provides insights into the innovative healthcare model implemented in this cutting edge cancer center, which proudly stood as the first of its kind outside the US to integrate the prestigious MD…

UK Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving the European Atomic Energy Community (Euratom) on cancer care in the UK. “The UK relies on Euratom for the diagnosis…

Austria Dr. Christoph Zielinski, head of the organizational unit of the Comprehensive Cancer Center of Vienna (CCC), a representative of the Austrian oncological community, provides an insight into the key activities of the center. He also gives an overview of the current state of the Austrian healthcare and oncology ecosystem as…

Algeria Long considered maladies of affluent urban populations in mature Western economies, non communicable diseases (NCDs)– such as diabetes, cancer, chronic respiratory and cardiovascular diseases – have been spreading silently and unchecked throughout the African continent to the point where they are now reaching epidemic proportions and becoming a major determinant…

Taiwan James Yang, Director of the Department of Oncology at National Taiwan University Hospital and Director of the Graduate Institute of Oncology at National Taiwan University, discusses the important role of oncology research in developing the Taiwanese pharmaceutical market as well as the new National Taiwanese University Cancer Center (which will…

Taiwan Chen Min-Che, founder and managing director of Asclepiumm, provides insights into the main milestones reached and the new partnership opportunities considered by this exciting biotech company, whose Antibody Switch-on Cytotoxicity (ASC) technology platform could contribute to bringing onto the global market a novel class of “smart cell-penetrating proteins” in multiple…

Italy Professor Angelo Corti, Director of the Experimental Oncology division of the SRSI, discusses approaches to oncology research and the institute´s significant contribution to the field in Italy. What is the philosophy of the SRSI’s oncology division towards oncology research? The development of new strategies to improve cancer prevention, detection and…

Mexico Patrick Troop, CEO at Pharma Tycsa, explains the company’s unique business approach in Mexico developing “clinical pharmacies” model to address chronic diseases treatment in the points of care and the importance of public and private partnerships to enhance the national health system. Could you please introduce to our international the…

Switzerland Helsinn is a leader in cancer supportive care, and Vice Chairman and CEO Riccardo Braglia enthusiastically discusses the Group’s entrance into the field of oncology therapeutics and the launch of the new Helsinn Investment Fund.   Helsinn Advanced Synthesis in Biasca is a very advanced site capable of synthesizing high…

Luxembourg In an exclusive interview, Luxembourg’s dedicated Minister for Health provides a passionate insight into how the country is developing an improved and integrated healthcare system with patients at the very centre of their efforts.   We could play a bigger role in the industry by becoming an innovative hub for…

Mexico Mayra Galindo Leal, general director of the Mexican Association of the Fight Against Cancer (AMLCC) provides an overview of the main milestones of this association that stands as the most important patient organization for cancer in Mexico, her expectations towards the pharmaceutical industry, and the main challenges she faces when…